GSK plc stock (GB0009252882): Analysts forecast 9% upside potential

GSK plc, the UK-based pharmaceutical giant, continues to draw attention from Wall Street analysts who see growth potential in its stock. Recent forecasts indicate an average price target of GBX 2,034.29, representing a 9.25% upside from the current price of GBX 1,862, based on input from seven analysts tracked by MarketBeat as of 2026. The ratings include two 'Buy' recommendations amid a consensus leaning toward 'Moderate Buy'.

As of: 12.05.2026

By the editorial team – specialized in equity coverage.

GSK plc: core business model

GSK plc operates as a science-led global biopharma company focused on research, development and delivery of innovative products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. The company invests heavily in R&D to address unmet medical needs, particularly in HIV, oncology, immunology and respiratory diseases. Its business model emphasizes a balanced portfolio across specialty medicines and established products, serving patients in over 150 countries.

GSK's strategy includes a shift toward specialty medicines, which now represent a growing portion of revenues. This transition supports long-term growth, with the company leveraging its pipeline of over 40 products in late-stage development. For US investors, GSK's NYSE listing provides direct access to its ADR (ticker: GSK), trading around $38-40 USD recently, reflecting its exposure to the world's largest pharma market.

Main revenue and product drivers for GSK plc

Vaccines remain a cornerstone, led by Shingrix for shingles prevention, which generated billions in peak sales. Specialty medicines like Dovato and Cabenuva for HIV treatment are key growth drivers, showing strong uptake in the US. General medicines, including respiratory drugs like Advair, continue to contribute steadily despite patent expirations.

In recent quarters, GSK reported earnings beats, such as $1.27 per share for Q3 2024 versus consensus of $1.16, per Zacks as of Jun 2025. Next earnings for Q2 2025 are expected at $1.12-1.28 per share. These figures underscore resilient demand, particularly in the US where vaccines and HIV therapies drive significant revenue.

Industry trends and competitive position

The global pharma sector faces patent cliffs but benefits from innovation in biologics and vaccines. GSK holds a strong position with its diversified portfolio, competing against Pfizer, Moderna in vaccines and Gilead in HIV. Recent analyst optimism reflects confidence in GSK's pipeline and cost discipline post-Haleon spin-off.

Why GSK plc matters for US investors

GSK's US operations account for a substantial revenue share, bolstered by its NYSE ADR listing. Products like Shingrix have captured significant market share in the US, where aging demographics boost demand. Exposure to US healthcare spending makes GSK relevant for retail investors tracking global pharma leaders with domestic footprints.

Conclusion

GSK plc maintains a solid position in biopharma with analyst targets signaling upside potential and a history of earnings beats. Its focus on high-growth areas like vaccines and specialty medicines positions it well amid industry shifts. US investors can monitor upcoming earnings and pipeline updates for further insights into performance.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.